Results 131 to 140 of about 766 (143)

Production of certified reference materials for the sports doping control of the REV-ERB agonist SR9009.

Drug Testing and Analysis, 2018
Two human metabolites of the REV-ERB agonist SR9009, identified by researchers with an interest in sports doping control, have been synthesized and assessed for purity.
S. Davies, Benjamin K. H. Chan, Michael Moawad, T. Garrett, L. Brooker, Rima Chakrabarty   +5 more
semanticscholar   +3 more sources

P245 The Rev-erba clock agonist (SR9009) protects against house dust mite induced T2 asthma

New insights from the fundamental sciences
Asthma is a highly rhythmic disease with increased airway sputum eosinophilia and decline in lung function (FEV1) observed early morning.1 We have previously shown that the time of day of allergen challenge in mice governs the amplitude of the resulting airway hyperresponsiveness (AHR).
A. Chakraborty, J. Cain, R. Maidstone, V. Deugi, N. Begley, D. Bechtold, J. Gibbs, H. Durrington   +7 more
semanticscholar   +3 more sources

REV-ERBβ is Required to Maintain Normal Wakefulness and the Wake-Inducing Effect of dual REV-ERB Agonist SR9009

Biochemical Pharmacology, 2018
Graphical abstract Figure. No Caption available. Abstract Circadian signaling regulates and synchronizes physiological and behavioral processes, such as feeding, metabolism, and sleep cycles.
Ariadna Amador, T. Kamenecka, Laura A. Solt, T. Burris   +3 more
semanticscholar   +3 more sources

SR9009 inhibits prostate cancer subtype 1 through regulating LXRα/FOXM1 pathway independently of REV-ERBs

European Urology, 2022
H. Xu, J. Ai, L. Yang, Q. Wei
semanticscholar   +2 more sources

Rev-erbα Agonist (SR9009) Attenuates House Dust Mite (HDM)-induced Lung Inflammation in a Preclinical Mouse Model of Allergic Asthma

D21. TERMINATOR: CONTROL OF AIRWAY INFLAMMATION AND IMMUNE RESPONSE IN ASTHMA
S. Duraisamy, C. Prasad, M. Castro, T.P. Burris, I. Sundar   +4 more
semanticscholar   +2 more sources

ASN892713 Supplemental Material - Supplemental material for Chemotherapeutic Effect of SR9009, a REV-ERB Agonist, on the Human Glioblastoma T98G Cells

2019
Supplemental material, ASN892713 Supplemental Material for Chemotherapeutic Effect of SR9009, a REV-ERB Agonist, on the Human Glioblastoma T98G Cells by Paula M. Wagner, Natalia M. Monjes and Mario E.
Wagner, Paula M., Monjes, Natalia M., Guido, Mario E.   +2 more
openaire   +1 more source

Effects of REV ERB agonist II SR9009 on canine osteosarcoma cells in 3D cell culture

2021
Masterarbeit Wien, FH Campus Wien ...
openaire   +1 more source

Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers

Expert Opinion on Drug Metabolism & Toxicology
Introduction Cyclophosphamide (CPA) is a widely used broad-spectrum antitumor drug with severe hepatotoxicity. Finding an effective way to mitigate the hepatotoxicity caused by CPA is a challenge in its clinical application.
Jinyi Wang, Jialu Cui, Tingying Hao, Qi Zhang, Yutong Chen, Lianxia Guo, Yongbin Tong, Dong Dong   +7 more
semanticscholar   +1 more source

EXTH-06. Disrupting BMAL1 enhances Temozolomide efficacy and abolishes circadian timing effects in pediatric high-grade gliomas

Neuro-Oncology
While circadian regulation of chemosensitivity is emerging as a therapeutic avenue in adult gliomas, its role in pediatric high-grade gliomas (pHGGs) remains unexplored.
Ella A. Nettnin, Cesar A. Garcia, Fudhial Sayed, M. I. B. Guinle, Erin M. Gibson, L. Prolo   +5 more
semanticscholar   +1 more source

USE OF SMALL MOLECULE SR9009 IN ANTI-AGING AND ALLEVIATION OF CHRONIC INFLAMMATION CAUSED BY AGING

2022
JING QING, GAO LIBIN, LIU ZHIHUA, WANG YAHONG   +3 more
openaire   +1 more source